Dr. Flinn on Next Steps With Venetoclax Plus Obinutuzumab in CLL

Ian Flinn, MD
Published: Friday, Jan 05, 2018



Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses next steps with venetoclax (Venclexta) and obinutuzumab (Gazyva) in patients with previously untreated chronic lymphocytic leukemia (CLL).

Following the positive results of the phase Ib study, this combination is being evaluated in a phase III randomized trial in Germany. Flinn predicts that this trial will be positive, and demonstrate the viability of this option for this patient population.
SELECTED
LANGUAGE


Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses next steps with venetoclax (Venclexta) and obinutuzumab (Gazyva) in patients with previously untreated chronic lymphocytic leukemia (CLL).

Following the positive results of the phase Ib study, this combination is being evaluated in a phase III randomized trial in Germany. Flinn predicts that this trial will be positive, and demonstrate the viability of this option for this patient population.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication
x